Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Korábbi kezelés

• Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors.
• Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases.
• Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study.

Más betegség

• Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection.
• Active autoimmune diseases requiring systemic immunosuppressive therapy.
• Clinically significant, severe, or uncontrolled cardiovascular diseases.
• Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers).
• Severe gastrointestinal conditions that may significantly affect the absorption of oral medications.
• Known severe allergic reactions to any of the study drugs or their excipients.

Egyéb

• Pregnant or breastfeeding women.

• Age 18 years and older at the time of informed consent.
• Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).
• Relapsed or refractory disease, having previously received at least two lines of systemic therapy.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
• Presence of measurable disease.
• Adequate hematologic, hepatic, and renal function.
• Willingness to use effective contraception methods during the study and for a specified period after the last dose.
• Willing and able to provide written informed consent and comply with the study protocol.